Tenaya Q3 Loss Beats Estimates; $66.8M Cash Runs Into Q4 2027
TNYA is trading near its 52-week low of $0.351 (7.4% above the low).
Summary
Tenaya posted an $18.94M Q3 net loss, or $0.08 per basic share, with an operating loss of $19.57M that came in better than the $22.67M consensus from three analysts. Operating expenses were $21.27M, helped by lower R&D spending including reduced stock-based compensation. Cash stood at $66.8M as of September 30, which management says funds operations into Q4 2027 — a long runway for a company this small. The quarter also carries the FDA's RMAT designation for TN-401, granted in September on positive interim RIDGE-1 data. Near-term news flow is defined: longer-term MyPEAK-1 follow-up and additional interim RIDGE-1 data are both expected by year end, with at least one Phase 2 TN-301 trial planned for H2 2027.
At the time of this announcement, TNYA was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.3M. The 52-week trading range was $0.35 to $1.56. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.